Medical Strategy GmbH
9 followers
1-10 employees
News
Gilead to buy cancer drugmaker Immunomedics for $21 billion
The deal provides Gilead access to Immunomedics' breast cancer treatment drug, Trodelvy, which was granted an accelerated FDA approval in April. Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share, representing a premium of about 108% overhttps://finance.yahoo.com/news/gilead-buy-cancer-drugmaker-immunomedics-024148882.htmlhttps://register.gotowebinar.com/register/5023689927188172815
About us
Medical Strategy gehört zu den führenden, unabhängigen Healthcare-Investmentberatern Europas. Das Unternehmen konzentriert sich im Rahmen seiner Kernkompetenz ausschließlich auf das Management und die Beratung von Aktienportfolios aus dem Gesundheitsbereich. http://www.medicalstrategy.de/impressum/